epithelial-mesenchymalrestraint重点.PDFVIP

Author Manuscript Published OnlineFirst on November 26, 2013; DOI: 10.1158/0008-5472.CAN-13-1313 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint 1* 1* 1* 1 1 Xiaoming Ju , Mathew C. Casimiro , Michael Gormley , Hui Meng , Xuanmao Jiao , Sanjay 1 1 1 1 1 2,3 Katiyar , Marco Crosariol , Ke Chen , Min Wang , Andrew A. Quong , Michael P. Lisanti , Adam Ertel1, and Richard G. Pestell1,2 Departments of 1Cancer Biology and 2Medical Oncology, 3Stem Cell Biology and Regenerative Medicine, Thomas Jefferson University, Kimmel Cancer Center, 233 South 10th Street, Philadelphia, PA19107 * Contributed equally to the manuscript Correspondence: Richard G. Pestell, M.D., Ph.D. Departments of Cancer Biology Medical Oncology, Thomas Jefferson University, 233 S. 10th Street, Philadelphia, PA 19107, Email: director@ Tel: 215-503-5692. Fax: 215-503-9334. Precis: This study reveals a novel function for cyclin D1 in mediating the expansion of prostate stem cells that contribute to prostate cancer. Running Title: Cyclin D1 Gene Network in Prostate Cancer Key Words: Cyclin D1, gene network, prostate cancer, siRNA, shRNA Conflicts of Interest: R.G.P. holds ownership interests ( $10,000) in, and serves as Founder of the biopharmaceutical companies ProstaGene, LLC and AAA Phoenix, Inc. R.G.P. additionally holds ownership interests (value unknown) for submitted and prosecuted patents. Downloaded from on June 16, 2017. © 2013 American Association for Cancer Research. Author Manu